Thalidomide for Lymphoma, Diffuse
This study is evaluating whether long-term thalidomide therapy is safe and effective for people with multiple myeloma.
See full descriptionAbout the trial for Lymphoma, Diffuse
Treatment Groups
This trial involves 2 different treatments. Thalidomide is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
About The Treatment
Side Effect Profile for SLE/Cutaneous Lupus With Thalidomide
Eligibility
This trial is for patients born any sex aged 18 and older. There are 2 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Thalidomide will improve 1 primary outcome and 3 secondary outcomes in patients with Lymphoma, Diffuse. Measurement will happen over the course of Up to five years.
Who is running the study
Principal InvestigatorPatient Q & A Section
What are common treatments for lymphoma, diffuse?
There is no cure for lymphoma, so treatment is focusing to decrease symptoms. Immunotherapy may improve the patient's quality of life. Chemotherapy and/or other antimullerian hormone drugs may decrease tumour mass at diagnosis. Radiation"http://www.nhs.uk/professionals/pathologists/pathology-pathlab/path-diagnosis/pathology-diagnosis.htm\".
What are the signs of lymphoma, diffuse?
Sequestration of lymphoid tissues leads to the formation of nodules in the lungs. There are non-specific radiographic features of serendipity, although there is no definite radiological finding for malignant phase lesions of Hodgkin's lymphoma. Recent findings show that serendipity is found to be a manifestation of the disease process.
How many people get lymphoma, diffuse a year in the United States?
Although more information on lymphoma is needed for subspecialty lymphoma and mycosis fungoides, the high incidence of all lymphomas in the current study is consistent with rates in other industrialized countries. The high incidence rate of Burkitt's lymphoma is also consistent with the very high incidence in Africa. In comparison with Hodgkin lymphoma and indolent, bulky non-Hodgkin lymphomas, the lower incidence of the other types of diffuse lymphoma is similar to those reported in other industrialized countries. The low incidence of chronic lymphocytic lymphoma is also similar, especially when compared with low incidence rates of chronic lymphocytic leukemia in the United States.
What is lymphoma, diffuse?
Lymphoma-diffuse is the commonest type of lymphoma occurring in the UK. It usually appears after the age of 60 years. Most people have non-Hodgkin lymphoma and in the UK, there are about 1,000 new cases of non-Hodgkin lymphoma a year. Half of the cases of lymphoma-diffuse occur in people without any family history of the disease. We think that genes and environment may well be involved.
What causes lymphoma, diffuse?
Lymphoma is a group of malignancies in which the body's cells acquire the ability to grow uncontrollably but a particular type of B cell, which has developed as a result of a chronic infection or autoimmune disease, gains new genetic alterations and becomes a neoplasm. It is an illness which is relatively rare, with an incidence that is increasing in industrialized countries around the world. These types of lymphomas are commonly called Hodgkin's lymphoma, non-Hodgkin's lymphoma and large B cell lymphomas.
Can lymphoma, diffuse be cured?
This is the first report of long-term survival during therapy after bone marrow transplantation in a case of aggressive diffuse large B-cell lymphoma involving the spleen.
Has thalidomide proven to be more effective than a placebo?
Thalidomide can produce clinically significant improvements in symptoms and quality of life, which is comparable to those achieved with chemotherapy in patients with lymphoma. The side effects of thalidomide are generally modest compared with that of cytotoxic chemotherapy. Thalidomide may be an effective first-line therapy for patients with lymphoma who are not responding to chemotherapy.
Have there been other clinical trials involving thalidomide?
Because more than 70% of patients with mantle cell lymphoma develop CNS involvement, patients at high risk for such complications should be treated on a clinical trial that specifically involves this complication. In particular, it is suggested that patients with high-risk mantle cell lymphoma should be enrolled in trials or the use of prophylactic antimetabolites should be evaluated on a phase III trial. Results from a recent paper are based on the data from the current clinical trials. Clin Cancer Res; 21(9); 2277-9. ©2013 AACR.
What does thalidomide usually treat?
Thalidomide is effective as initial treatment for relapsed or refractory ALK+ or ALK- ALK+ systemic ALK+ B-chronic lymphocytic leukemia. However, due to significant toxicity issues with thalidomide, it is rarely the first-line choice of drug. Thalidomide has been shown in multiple clinical trials in refractory ALK+ CTCL to induce complete or partial molecular responses and durable remissions in more than half of patients with ALK+ disease.
Who should consider clinical trials for lymphoma, diffuse?
The following patient characteristics should be considered when deciding on clinical trial treatment for lymphoma, diffuse: performance status 0, no symptoms or weight loss; ECOG performance status 0, symptom-limited disease; and age ≤50 years.
What is the primary cause of lymphoma, diffuse?
All of the diagnoses have not been reviewed in a large case series with the exception of lymphoma diffuse. The primary cause of lymphoma diffuse is not known, and the role of Epstein-Barr virus is disputed.
What is the latest research for lymphoma, diffuse?
Due to this research, most lymphomas are treated as benign disorders for which a surgery intervention is done. A surgery can help to remove the tumor completely, but it is not a treatment for the lymphoma, but only for the removal of it. A lymphoma and diffuse is not one of the rare tumours, therefore, the patients of any age who have it need to be monitored, as the disease is always in danger of becoming inoperable.